Department for Infectious Diseases, Hvidovre Hospital, University Hospital of Copenhagen, Copenhagen, Denmark.
Vaccine. 2012 Nov 19;30(49):7067-71. doi: 10.1016/j.vaccine.2012.09.052. Epub 2012 Oct 2.
Continued research is needed to evaluate and improve the immunogenicity of influenza vaccines in HIV infected patients. We aimed to determine the antibody responses after one or two doses of the AS03-adjuvanted pandemic influenza A (H1N1) vaccine in HIV infected patients.
Following the influenza season 2009/2010, 219 HIV infected patients were included and divided into three groups depending on whether they received none (n=60), one (n=31) or two (n=128) doses of pandemic influenza A (H1N1) vaccine. At inclusion, antibody titers for all patients were analyzed and compared to pre-pandemic antibody titers analyzed from serum samples in a local storage facility.
4-9 months after a single immunization, we found a seroprotection rate of 77.4% and seroconversion rate of 67.7%. After two immunizations the rates increased significantly to seroprotection rate of 97.7% and seroconversion rate of 86.7%.
A single dose of AS03-adjuvanted pandemic influenza A (H1N1) vaccine created an adequate immune response in HIV infected patients lasting as long as 4-9 months. Two doses improved the immunogenicity further.
需要继续研究以评估和提高 HIV 感染者流感疫苗的免疫原性。我们旨在确定感染 HIV 的患者接种一剂或两剂 AS03 佐剂的大流行性流感 A（H1N1）疫苗后的抗体反应。
在 2009/2010 年流感季节之后，纳入了 219 名 HIV 感染患者，并根据他们是否接受了无剂量（n=60）、一剂（n=31）或两剂（n=128）大流行性流感 A（H1N1）疫苗，将他们分为三组。在纳入时，对所有患者的抗体滴度进行了分析，并与当地储存设施中分析的大流行前抗体滴度进行了比较。
在单次免疫后 4-9 个月，我们发现血清保护率为 77.4%，血清转化率为 67.7%。两次免疫后，这些比率显著增加，血清保护率达到 97.7%，血清转化率达到 86.7%。
一剂 AS03 佐剂的大流行性流感 A（H1N1）疫苗在 HIV 感染患者中产生了足够的免疫反应，持续时间长达 4-9 个月。两剂可进一步提高免疫原性。
